Correlation Between Aslan Pharmaceuticals and Achilles Therapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Aslan Pharmaceuticals and Achilles Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Aslan Pharmaceuticals and Achilles Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Aslan Pharmaceuticals and Achilles Therapeutics PLC, you can compare the effects of market volatilities on Aslan Pharmaceuticals and Achilles Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Aslan Pharmaceuticals with a short position of Achilles Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Aslan Pharmaceuticals and Achilles Therapeutics.

Diversification Opportunities for Aslan Pharmaceuticals and Achilles Therapeutics

-0.57
  Correlation Coefficient

Excellent diversification

The 3 months correlation between Aslan and Achilles is -0.57. Overlapping area represents the amount of risk that can be diversified away by holding Aslan Pharmaceuticals and Achilles Therapeutics PLC in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Achilles Therapeutics PLC and Aslan Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Aslan Pharmaceuticals are associated (or correlated) with Achilles Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Achilles Therapeutics PLC has no effect on the direction of Aslan Pharmaceuticals i.e., Aslan Pharmaceuticals and Achilles Therapeutics go up and down completely randomly.

Pair Corralation between Aslan Pharmaceuticals and Achilles Therapeutics

Given the investment horizon of 90 days Aslan Pharmaceuticals is expected to under-perform the Achilles Therapeutics. In addition to that, Aslan Pharmaceuticals is 3.25 times more volatile than Achilles Therapeutics PLC. It trades about -0.35 of its total potential returns per unit of risk. Achilles Therapeutics PLC is currently generating about 0.05 per unit of volatility. If you would invest  92.00  in Achilles Therapeutics PLC on August 29, 2024 and sell it today you would earn a total of  15.00  from holding Achilles Therapeutics PLC or generate 16.3% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthVery Weak
Accuracy27.2%
ValuesDaily Returns

Aslan Pharmaceuticals  vs.  Achilles Therapeutics PLC

 Performance 
       Timeline  
Aslan Pharmaceuticals 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Aslan Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of very healthy essential indicators, Aslan Pharmaceuticals is not utilizing all of its potentials. The latest stock price disarray, may contribute to short-term losses for the investors.
Achilles Therapeutics PLC 

Risk-Adjusted Performance

11 of 100

 
Weak
 
Strong
Good
Compared to the overall equity markets, risk-adjusted returns on investments in Achilles Therapeutics PLC are ranked lower than 11 (%) of all global equities and portfolios over the last 90 days. Despite quite weak technical indicators, Achilles Therapeutics disclosed solid returns over the last few months and may actually be approaching a breakup point.

Aslan Pharmaceuticals and Achilles Therapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Aslan Pharmaceuticals and Achilles Therapeutics

The main advantage of trading using opposite Aslan Pharmaceuticals and Achilles Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Aslan Pharmaceuticals position performs unexpectedly, Achilles Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Achilles Therapeutics will offset losses from the drop in Achilles Therapeutics' long position.
The idea behind Aslan Pharmaceuticals and Achilles Therapeutics PLC pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.

Other Complementary Tools

Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Commodity Directory
Find actively traded commodities issued by global exchanges
Stocks Directory
Find actively traded stocks across global markets
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges